Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma
The BAC regimen appears effective and well tolerated in adult patients with rHGG, particularly in younger patients. Its alternating design may improve the median OS (29 vs. 19 months) and PRS (16 vs. 10 months) of patients with grade 4 gliomas while maintaining safety. As a practical option for those ineligible for clinical trials, BAC warrants further evaluation in prospective randomized studies to confirm its benefits and address the limitations of retrospective analysis.
Authors
- Ping-Chuan Liu (ORCID: https://orcid.org/0000-0003-2366-1314)
- Feng‐Chi Chang (ORCID: https://orcid.org/0000-0001-7267-6497)
- Chun‐Fu Lin (ORCID: https://orcid.org/0000-0001-5831-6620)
- Jau‐Ching Wu (ORCID: https://orcid.org/0000-0002-6996-3409)
- Chao-Yang Kuo (ORCID: https://orcid.org/0000-0001-8867-5683)
- Shih‐Chieh Lin (ORCID: https://orcid.org/0000-0003-3693-5476)
- Yiwei Chen (ORCID: https://orcid.org/0000-0003-3749-8087)
- M H Chen
- Yi-Yen Lee (ORCID: https://orcid.org/0009-0004-1110-6174)
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taipei University of Nursing and Health Science (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf157
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00